Bellicum
Pharmaceuticals Raises $34.4 Million in a Series B Financing
Funds
Will Expand Clinical Development of Company's Controlled Cellular
Immunotherapies
Full
Press Release Below.
SOURCE:
Bellicum Pharmaceuticals
HOUSTON,
Jan. 7, 2014 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. announced
today that it has completed a second and final closing of its Series B
financing, securing an additional $14.7 million and bringing the total raised
in the round to $34.4 million. Current investors provided the additional funding,
including AVG Ventures and Remeditex Ventures.
The
funding will be used to expand clinical development of Bellicum's lead cellular
immunotherapy product candidates.
"Bellicum
is well positioned within the highly promising field of cellular immunotherapy
with a technology that provides control over cells after they have been
administered to the patient," said Bellicum CEO Tom Farrell. "This
funding will be used to advance our two clinical programs in leukemia/lymphoma
and prostate cancer, and launch studies in additional indications where there
is urgent need for safer and more effective cell therapies."
Bellicum's
two lead clinical development programs utilize the Company's unique ability to
control cell therapies once inside the body. BPX-501 T cells contain the
Company's CaspaCIDe™ gene "safety switch," enabling physicians to
eliminate transplanted cells in the event they become harmful to the patient.
The product is being evaluated in a Phase I/II study to reduce or eliminate
Graft versus Host Disease in cancer patients undergoing hematopoietic stem cell
transplant.
BPX-201
dendritic cells contain the Company's DeCIDe ® gene "on
switch," which enables physicians to strategically target immune
activation for a more potent anti-tumor effect. It is being evaluated in a
Phase I clinical trial in patients with metastatic castrate-resistant prostate
cancer.
About
Bellicum Pharmaceuticals
Bellicum
is dedicated to developing safer and more effective cell therapies to treat
cancers and other serious, life-threatening diseases. The Company's cell
therapies are engineered with a gene "switch" that enables physicians
to activate or eliminate cells once inside the body to improve safety and
efficacy. Bellicum is advancing clinical programs in cellular transplants to reduce
or eliminate Graft versus Host Disease, and in prostate cancer with a
potentially more potent immunotherapy. For more information please visit www.bellicum.com
SOURCE
Bellicum Pharmaceuticals, Inc.
CONTACT:
Brad Miles, 646-513-3125, bmiles@bmccommunications.com, or Amy Bonanno,
646-513-3117, abonanno@bmccommunications.com
Web Site: http://www.bellicum.com
No comments:
Post a Comment